215 related articles for article (PubMed ID: 17006667)
1. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
2. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.
Press RD; Willis SG; Laudadio J; Mauro MJ; Deininger MW
Blood; 2009 Sep; 114(13):2598-605. PubMed ID: 19625707
[TBL] [Abstract][Full Text] [Related]
3. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
Iqbal Z; Aleem A; Iqbal M; Naqvi MI; Gill A; Taj AS; Qayyum A; ur-Rehman N; Khalid AM; Shah IH; Khalid M; Haq R; Khan M; Baig SM; Jamil A; Abbas MN; Absar M; Mahmood A; Rasool M; Akhtar T
PLoS One; 2013; 8(2):e55717. PubMed ID: 23409026
[TBL] [Abstract][Full Text] [Related]
4. Molecular resistance: an early indicator for treatment change?
Fava C; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):79-87. PubMed ID: 22285607
[TBL] [Abstract][Full Text] [Related]
5. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
Khorashad JS; de Lavallade H; Apperley JF; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
J Clin Oncol; 2008 Oct; 26(29):4806-13. PubMed ID: 18645191
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir.
Azad NA; Shah ZA; Pandith AA; Khan MS; Rasool R; Rasool J; Aziz SA
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1479-1485. PubMed ID: 29936718
[TBL] [Abstract][Full Text] [Related]
7. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Hughes T; Deininger M; Hochhaus A; Branford S; Radich J; Kaeda J; Baccarani M; Cortes J; Cross NC; Druker BJ; Gabert J; Grimwade D; Hehlmann R; Kamel-Reid S; Lipton JH; Longtine J; Martinelli G; Saglio G; Soverini S; Stock W; Goldman JM
Blood; 2006 Jul; 108(1):28-37. PubMed ID: 16522812
[TBL] [Abstract][Full Text] [Related]
8.
Benjamin ESB; Ravindra N; Rajamani BM; Anandan S; Kausalya B; Veldore V; Mathews V; Velayudhan SR; Balasubramanian P
Leuk Lymphoma; 2021 Jun; 62(6):1528-1531. PubMed ID: 33478278
[No Abstract] [Full Text] [Related]
9.
Azevedo AP; Reichert A; Afonso C; Alberca MD; Tavares P; Lima F
Clin Med Insights Oncol; 2017; 11():1179554917702870. PubMed ID: 28469513
[TBL] [Abstract][Full Text] [Related]
10. Follow-up of the tumor load in patients with de novo chronic myeloid leukemia and in complete cytogenetic remission treated with imatinib in Colombia.
Guevara G; González JA; Lopera DE; González M; Saavedra JD; Lobaton JF; Duque JE
Colomb Med (Cali); 2012 Oct; 43(4):267-72. PubMed ID: 24893299
[TBL] [Abstract][Full Text] [Related]
11. Retraction: Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era.
PLOS ONE Editors
PLoS One; 2024; 19(4):e0301946. PubMed ID: 38568938
[No Abstract] [Full Text] [Related]
12. An Imatinib-non-responsive patient with an
Crespiatico I; Bossi E; Brioschi F; Piazza R; Mologni L; Gambacorti-Passerini C
Clin Case Rep; 2020 Jan; 8(1):71-74. PubMed ID: 31998490
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Müller MC; Cortes JE; Kim DW; Druker BJ; Erben P; Pasquini R; Branford S; Hughes TP; Radich JP; Ploughman L; Mukhopadhyay J; Hochhaus A
Blood; 2009 Dec; 114(24):4944-53. PubMed ID: 19779040
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Cortes J; Jabbour E; Kantarjian H; Yin CC; Shan J; O'Brien S; Garcia-Manero G; Giles F; Breeden M; Reeves N; Wierda WG; Jones D
Blood; 2007 Dec; 110(12):4005-11. PubMed ID: 17785585
[TBL] [Abstract][Full Text] [Related]
15. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.
O'Hare T; Eide CA; Deininger MW
Blood; 2007 Oct; 110(7):2242-9. PubMed ID: 17496200
[TBL] [Abstract][Full Text] [Related]
16. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
17. Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India.
Hazarika G; Kalita MJ; Das PP; Kalita S; Dutta K; Lahkar L; Rajkonwar A; Idris MG; Khamo V; Kusre G; Medhi S
Biochem Genet; 2024 Feb; ():. PubMed ID: 38363412
[TBL] [Abstract][Full Text] [Related]
18. 3-Aroyl-1,4-diarylpyrroles Inhibit Chronic Myeloid Leukemia Cell Growth through an Interaction with Tubulin.
La Regina G; Bai R; Coluccia A; Famiglini V; Passacantilli S; Naccarato V; Ortar G; Mazzoccoli C; Ruggieri V; Agriesti F; Piccoli C; Tataranni T; Nalli M; Brancale A; Vultaggio S; Mercurio C; Varasi M; Saponaro C; Sergio S; Maffia M; Coluccia AML; Hamel E; Silvestri R
ACS Med Chem Lett; 2017 May; 8(5):521-526. PubMed ID: 28523104
[TBL] [Abstract][Full Text] [Related]
19. Identification of galectin-1 as a novel mediator for chemoresistance in chronic myeloid leukemia cells.
Luo W; Song L; Chen XL; Zeng XF; Wu JZ; Zhu CR; Huang T; Tan XP; Lin XM; Yang Q; Wang JZ; Li XK; Wu XP
Oncotarget; 2016 May; 7(18):26709-23. PubMed ID: 27050374
[TBL] [Abstract][Full Text] [Related]
20. Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.
Rostami G; Hamid M; Yaran M; Khani M; Karimipoor M
J Hum Genet; 2015 May; 60(5):253-8. PubMed ID: 25740611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
